secwatch.observer — SEC 8-K summary
======================================

Issuer:     Werewolf Therapeutics, Inc. (HOWL)
CIK:        0001785530
Form:       8-K
Filed at:   2026-02-13T23:59:59+00:00
Accession:  0001193125-26-051455
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.05, 5.02, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Werewolf Therapeutics cuts 64% of workforce; CFO and CMO depart; appoints new principal financial officer
--------------------------------------------------------------------------------

- Reduction in force affecting 64% of workforce; expected completion by Feb 13, 2026.
- Estimated one-time charge of ~$4.1 million in Q1 2026 for severance and benefits.
- CFO Timothy Trost and CMO Randi Isaacs resign effective Feb 13, 2026; enter 6-month consulting agreements at $250/hour.
- Michael Urban named principal financial and accounting officer, effective Feb 13, 2026.
- Company evaluating strategic alternatives for WTX-124 and WTX-330 programs; no assurance of transaction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785530/000119312526051455/0001193125-26-051455-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785530/000119312526051455/d110809d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-051455

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer